CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Descent (XinCOOL)
Phase: NA
Conditions: Body Fat Disorder
Sponsor: Allergan

 
   
 
 
 
         NCT04142450 
 
Study ID: MED-MA-PLS-0633  
 
 
Title: CoolSculpting® the Upper Arms and Inner Thighs in Participants of 
Chinese Descent (XinCOOL) 
 
                  
 
Protocol Date: October 2, 2019 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 1 of 70
CONFIDENTIAL
CLINICAL INVESTIGATION PLAN
PROTOCOL MED-MA-PLS-0633
CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese 
Descent (XinCOOL)
Protocol Number:
MED-MA-PLS-0633
Investigational Product:
CoolSculpting®
Phase:
Post-marketing
Sponsor:
Allergan Sales, LLC 
5 Giralda Farms
Madison, NJ 07940
USA
Serious Adverse Event Reporting
Email:
CoolSculptingProductSurveillance@allergan.com
Allergan Device Medical Safety 
Physician Contact Information
Allergan plc
95 Corporate Drive
Bridgewater, NJ 08807, USA
Protocol Date:
02 October 2019
Protocol Version:
Version 1.0
CONFIDENTIAL
This protocol may not be reproduced or communicated to a third party without the 
written permission of Allergan Sales, LLC.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 2 of 70
CONFIDENTIAL
1
PROTOCOL APPROVAL SIGNATURES
Protocol Title:
CoolSculpting® the Upper Arms and Inner Thighs in Participants of 
Chinese Descent (XinCOOL)
Protocol Number:
MED-MA-PLS-0633
This study will be conducted in compliance with the clinical study protocol (and amendments, if 
applicable), International Organization for Standardization (ISO) 14155(2011), guidelines for 
current Good Clinical Practice (GCP) and applicable regulatory requirements.
Sponsor Signatories
Signature
Date
Signature
Date

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 3 of 70
CONFIDENTIAL
2
SYNOPSIS
Protocol Number: MED-MA-PLS-0633
Title:
CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Descent (XinCOOL)
Investigational Product:
CoolSculpting®
Study Sites:
Approximately 2 to 3 study sites
Phase:
Post-marketing
Objective:
The objective of this study is to evaluate the safety and effectiveness of the Allergan CoolSculpting®
system using CoolAdvantage applicators for non-invasive subcutaneous fat reduction of the upper arms 
and inner thighs in participants of Chinese descent.
Study Design:
This is a multi-center, prospective, open-label, nonrandomized, interventional cohort, medical device 
post-marketing study. 
Number of Participants: 
Approximately 42 participants will be enrolled.
Treatment:
Participants will undergo CoolSculpting treatment(s) in an outpatient clinical setting using 
CoolAdvantage and/or CoolAdvantage Petite applicators. Each participant will undergo a single treatment 
session that comprises timed segments of cooling followed by 2 minutes of manual massage. Each treated 
arm will have up to two timed segments (or cycles) in the treatment session, each treated thigh will have 
one timed segment (or cycle) in the treatment session. Treatments will be administered according to the 
Canadian CoolSculpting System User Manual.
Study Duration:
Screening (8 days), enrollment, and follow-up is expected to take approximately 3 months in total for 
each participant.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 4 of 70
CONFIDENTIAL
Study Population:
To be eligible to participate, participants must meet all of the inclusion criteria and none of the exclusion 
criteria listed below.
Inclusion Criteria
1.
Participant (healthy volunteers) has read and signed the study written informed consent form.
2.
Male or female participant ≥18 years of 1st or 2nd generation, non-mixed race, Chinese descent.
3.
Participant has clearly visible and palpable fat on the left and right lower aspects of the upper arms 
and/or left and right inner thighs, which in the investigator’s opinion is appropriate and may benefit 
from the treatment.
4.
Participant has not had weight change fluctuations exceeding 4.5 kg (or 5% of body weight) in the 
preceding month.
5.
Participant has a body mass index (BMI) of ≥18.5 to ≤30. A BMI is defined as weight in kilograms 
divided by height in meters squared (kg/m2). 
6.
Participant agrees to maintain weight (ie, within 5% of body weight) by not making any changes in 
diet or exercise routine during the course of the study.
7.
Participant agrees to have photographs taken of the treatment area(s) during the scheduled time 
periods.
 
Exclusion Criteria
1.
Participant has a history of an invasive fat reduction procedure (eg, liposuction, surgery, lipolytic 
agents, etc), or implants in or immediately adjacent to the area of intended treatment.
2.
Participant has a history of prior surgery or scar tissue on the arms and/or inner thighs related to 
the area being considered for treatment.
3.
Participant has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or 
paroxysmal cold hemoglobinuria.
4.
Participant has a known sensitivity to cold or has any condition with a known response to cold 
exposure that limits blood flow to the skin, such as cold urticaria, Raynaud’s disease, or Chilblains 
(pernio).

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 5 of 70
CONFIDENTIAL
5.
Participant with a clinically significant bleeding disorder, or concomitant use of oral or 
subcutaneous anticoagulants, or is taking any medication that in the investigator’s opinion may 
significantly increase the participant’s risk of bruising.
6.
Participant with a history of carpal tunnel syndrome, compartment syndrome, or deep vein 
thrombosis in the upper or lower extremities.
7.
Participant is currently taking or has taken diet pills or weight control supplements within the past 
6 months.
8.
Participant has any dermatological conditions, such as moderate to excessive skin laxity, infection, 
open wound, or scars in the location of the treatment sites that may interfere with the treatment or 
evaluation (stretch marks are not an exclusion).
9.
Participant has an active implanted device such as a pacemaker, defibrillator, drug delivery system, 
or any other metal-containing implant within or adjacent to the area being considered for treatment.
10. Participant is pregnant or intending to become pregnant in the next 3 months.
11. Participant is lactating or has been lactating in the past 6 months.
12. Participant is unable or unwilling to comply with the study requirements.
13. Participant is currently enrolled in a clinical study of any unapproved investigational device, 
investigational product, or any other type of medical research judged not to be scientifically or 
medically compatible with this study.
14. Participant has any other condition or laboratory value that would, in the professional opinion of 
the investigator, potentially affect the participant’s response or the integrity of the data or would 
pose an unacceptable risk to the participant.
15. Participant has had a non-invasive fat reduction and/or body contouring procedure in the area(s) of 
intended treatment within the past 12 months.
16. Participant needs to administer, or has a known history of subcutaneous injections, into the area(s)
of intended treatment (eg, cortisone, heparin, insulin) within the past 6 months.
17. Participant with known sensitivity or allergy to fructose, glycerin, isopropyl alcohol, or propylene 
glycol.
18. Participant with impaired peripheral circulation in the area to be treated.
19. Participant with neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy.
20. Participant with impaired skin sensation.
21. Participant with a history of hernia in or adjacent to the treatment area(s) site.
22. Participant with a skin condition such as eczema, dermatitis, or rashes in the area to be treated.
23. Participant diagnosed with a systemic fibrosing disease or fibrosis in the area intended or adjacent 
to the area to be treated.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 6 of 70
CONFIDENTIAL
Primary Endpoint:

Correct identification of baseline versus 12-week treatment images of the upper arms by at least 
two out of three blinded, independent reviewers. Success will be defined as at least 75% correct 
identification of the pre-treatment images.
Secondary Endpoints:
1.
Correct identification of baseline versus 12-week treatment images of the inner thighs by at least
two out of three blinded, independent reviewers.
2.
Participant response of ‘satisfied’ or ‘very satisfied’ for question 1 (overall satisfaction) on the
following CoolSculpting participant questionnaires at the 12-week visit:
a.
Upper arms
b.
Inner thighs
3.
Fat reduction using caliper measurements at 12-weeks compared to baseline for the following
areas:
a.
Upper arms
b.
Inner thighs
Safety Endpoints:

Adverse events (AEs), including serious AEs (SAEs); and adverse device events (ADEs),
including serious ADEs (SADEs).
.
Statistical Methods
Analysis Populations
1.
Per-protocol (PP) population: The PP population will consist of all treated participants followed
for 12 weeks and with weight change of no more than 5% of total body weight at the time the 12-
week images are taken. Because a weight change of more than 5% will affect the images, the
primary effectiveness analysis will be performed based on this study population. Participants who
do not complete treatment on the upper arms and/or inner thighs will not be included in the
effectiveness analyses.
2.
As-treated (AT) population: The AT population will consist of all treated participants regardless of
weight change, etc.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 7 of 70
CONFIDENTIAL
3.
Safety population: The safety population will consist of all the treated participants with at least 
one safety evaluation after the treatment. This population should be identical to the AT population. 
All safety data analyses will be performed based on the safety population.
Sample Size Determination
In this study, both arms and thighs will be evaluated by independent raters. The independent raters’ 
evaluations will be combined into one clinical judgement on each arm and thigh. The evaluations on arms 
and thighs will be considered as independent.
A previous study described that the rate of correct identification was 83%. Using 75% as the lower bound 
of the 95% confidence interval (CI), the ½-width of the 95% CI will be 8%.
Based on these assumptions, we will need 60 evaluable arms or 32 evaluable participants for the arm 
evaluations with the assumption that less than 10% of participants have only one arm evaluation 
available.  The same number of participants for thigh evaluations will be needed.
With an assumption that only 80% of all subjects will have both arms and thighs treated, we will need 38 
evaluable participants in total for the study. Adding a 10% attrition rate, we will need to enroll 
42 participants in the study.
Statistical Analyses
In general, disposition data, participant baseline and characteristics data, and concomitant therapy data 
will be summarized descriptively. The categorical variables will be presented with number and proportion 
while the continuous variables will be presented with mean, standard deviation, median, minimum, and 
maximum.
The primary effectiveness analysis will be based on the PP population. The number and proportion of 
participants with correct identification of baseline vs 12-week images of the upper arms by at least two 
out of three blinded, independent reviewers and the corresponding 95% CI of the proportion of 
participants with correct identification will be summarized.
The number and proportion of participants with correct identification of baseline vs 12-week images of 
the inner thighs by at least two out of three blinded, independent reviewers and the corresponding 95% CI 
of the proportion of participants with correct identification will be summarized.
Participants who have reported ‘Very satisfied’ or ‘Satisfied’ on each of the CoolSculpting participant 
questionnaires (upper arms and inner thighs) for question #1 (overall satisfaction) will be categorized as 
‘Satisfied.’ The numbers and proportions will be summarized and the 95% CI of the proportions will be 
provided.
Fat reduction at 12 weeks compared to baseline will be summarized descriptively.
The numbers and proportions of participants with AEs, SAEs, ADEs, and SADEs will be summarized. 
The numbers and proportions of participant-reported pain scores (0 to 10 scale) will be summarized.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 8 of 70
CONFIDENTIAL
TABLE OF CONTENTS
1
PROTOCOL APPROVAL SIGNATURES ..................................................................2
2
SYNOPSIS........................................................................................................................3
TABLE OF CONTENTS ..............................................................................................................8
List of In-text Tables.................................................................................................................11
3
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ..............................12
4
INTRODUCTION .........................................................................................................13
4.1
Background ...................................................................................................................13
Studies using CoolAdvantage applicators for the upper arms and inner 
4.1.1
thighs...................................................................................................................14
CoolSculpting Studies in Asian Participants ......................................................15
4.1.2
4.2
Rationale........................................................................................................................17
Benefit and Risks ................................................................................................17
4.2.1
4.2.1.1
Benefits .............................................................................................17
4.2.1.2
Risks..................................................................................................17
5
STUDY OBJECTIVE AND ENDPOINTS..................................................................19
5.1
Objectives......................................................................................................................19
5.2
Endpoints.......................................................................................................................19
6
INVESTIGATIONAL PLAN .......................................................................................20
6.1
Overall Study Design and Plan: Description.................................................................20
Schedule of Assessments ....................................................................................21
6.1.1
6.2
Discussion of Study Design ..........................................................................................22
6.3
Selection of Study Population .......................................................................................22
Number of Planned Participants .........................................................................22
6.3.1
Inclusion Criteria ................................................................................................22
6.3.2
Exclusion Criteria ...............................................................................................23
6.3.3
Removal of Participants from Therapy or Assessments .....................................24
6.3.4
6.4
CoolSculpting System ...................................................................................................25
CoolSculpting Description..................................................................................25
6.4.1
Identity of CoolSculpting System.......................................................................26
6.4.2
6.4.2.1
Control Unit ......................................................................................27
6.4.2.2
Applicator .........................................................................................28
Packaging and Labelling.....................................................................................29
6.4.3

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 9 of 70
CONFIDENTIAL
Method of Assigning Participants to Treatment Groups ....................................29
6.4.4
Blinding...............................................................................................................29
6.4.5
Prior and Concomitant Therapy..........................................................................29
6.4.6
Treatment Compliance........................................................................................29
6.4.7
7
TIMING OF STUDY PROCEDURES ........................................................................30
7.3
Duration of Treatment ...................................................................................................33
8
EFFECTIVENESS AND SAFETY ASSESSMENTS ................................................34
8.1
Effectiveness Assessments............................................................................................34
Photography ........................................................................................................34
8.1.1
Participant Satisfaction .......................................................................................34
8.1.2
Caliper Measurement..........................................................................................34
8.1.3
8.2
Safety Assessments .......................................................................................................35
Adverse Events ...................................................................................................35
8.2.1
8.2.1.1
Serious Adverse Events ....................................................................38
8.2.1.2
Unanticipated Serious Adverse Device Effect..................................40
Warnings and Precautions...................................................................................40
8.2.2
Other Laboratory Variables ................................................................................40
8.2.3
Other Safety Assessments...................................................................................40
8.2.4
8.3
Serious Adverse Event and Unanticipated Adverse Device Effect Reporting..............41
8.4
Data Safety Monitoring Board ......................................................................................41
Appropriateness of Measurements......................................................................41
8.4.1
9
STATISTICAL METHODS .........................................................................................42
9.1
Determination of Sample Size.......................................................................................42
9.2
Populations for Analyses...............................................................................................42
9.3
Statistical Analyses........................................................................................................43
Disposition, Baseline and Study Information .....................................................43
9.3.1

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 10 of 70
CONFIDENTIAL
9.3.1.1
Participant Disposition......................................................................43
9.3.1.2
Participant Baseline and Characteristics...........................................43
9.3.1.3
Concomitant Therapy........................................................................43
9.3.1.4
Treatment Compliance......................................................................43
Effectiveness Analyses .......................................................................................43
9.3.2
9.3.2.1
Primary Effectiveness Analysis ........................................................43
9.3.2.2
Secondary Analyses ..........................................................................43
Safety Analyses...................................................................................................44
9.3.3
9.3.3.1
Subgroup Analyses ...........................................................................44
Interim Analyses .................................................................................................44
9.3.4
9.4
Protocol Deviations .......................................................................................................44
10
QUALITY ASSURANCE AND QUALITY CONTROL...........................................45
10.1
Audit and Inspection .....................................................................................................45
10.2
Monitoring.....................................................................................................................45
10.3
Data Management and Coding......................................................................................45
11
RECORDS AND SUPPLIES........................................................................................46
11.1
Device Accountability...................................................................................................46
11.2
Financing and Insurance................................................................................................46
12
ETHICS ..........................................................................................................................47
12.1
Independent Ethics Committee or Institutional Review Board.....................................47
12.2
Ethical Conduct of the Study.........................................................................................47
12.3
Informed Consent ..........................................................................................................47
12.4
Participant Confidentiality ............................................................................................48
13
REPORTING AND PUBLICATION, INCLUDING ARCHIVING ........................49

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 11 of 70
CONFIDENTIAL
List of In-text Tables

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 12 of 70
CONFIDENTIAL
3
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
Abbreviation/Term
Definition
ADE
adverse device event
AE
adverse event
AT
as-treated
BMI
body mass index
CE
Conformité Européenne
CI
confidence interval
CRF
case report form
eCRF
electronic case report form
EDC
electronic data capture
FDA
Food and Drug Administration
GCP
Good Clinical Practice
HCG
human chorionic gonadotropin
ICF
informed consent form
IEC
independent ethics committee
IRB
institutional review board
ISO
International Organization for Standardization
NIFR
non-invasive fat reduction
PP
per-protocol
SADE
serious adverse device event
SAE
serious adverse event
SAP
statistical analysis plan
SD
standard deviation
TMF
trial master file
UADE
unanticipated adverse device effect

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 13 of 70
CONFIDENTIAL
4
INTRODUCTION
4.1
Background
CoolSculpting® is a non-invasive, clinically proven fat-reduction treatment that selectively 
targets adipocytes using a patented cooling technology. The CoolSculpting mechanism of action 
works by cooling the subcutaneous tissue (cryolipolysis procedure) that preferentially targets 
adipocytes which leads to controlled elimination of adipocytes (Manstein 2008, Zelickson 2009). 
Adipose tissue appears more preferentially sensitive to cold injury than skin and other tissues 
(eg, skin, muscle, and nerve) and the crystallization of cytoplasmic lipids in adipocytes occurs at 
temperatures well above the freezing point of water (Epstein 1970, Beacham 1980,
Manstein 2008).
In the USA, the CoolSculpting system first received US FDA clearance in 2010 for non-invasive 
fat reduction (NIFR) in the flank followed by clearance for the abdomen in 2012 (Bernstein 
2014). Further approvals were gained for visible fat bulges in the submental and submandibular 
area, thigh, along with bra fat, back fat, underneath the buttocks (also known as “banana roll”), 
and upper arm.
The CoolSculpting System was CE marked for fat layer reduction in 2009 and was initially 
approved in Canada in 2008. The clearance went to general fat layer reduction, without a 
specified treatment area. Up to now, the CoolSculpting system has gained clearance/approval in 
more than 70 countries.
The current CoolSculpting applicators (CoolAdvantage family, CoolMini, and CoolSmooth Pro) 
are however not cleared in China where the flanks and abdomen are the only approved body 
areas. Submissions to the Chinese regulatory authorities are therefore being planned to seek 
clearance for these applicators as well as to extend the number of body area indications to 
include the submental and submandibular areas, inner and outer thighs, and upper arms.
In order to increase the probability of success of achieving regulatory approval from the Chinese 
authorities for these applicators and body areas (given the majority of participants in the 
CoolSculpting clinical program and the subsequent reported CoolSculpting commercial 
experience were Caucasian), further CoolSculpting clinical data in Chinese participants are
required. 
The purpose of this study is to collect meaningful clinical data for the use of CoolSculpting in 
participants of Chinese descent (to be conducted in Canada) using the current CoolAdvantage 
and CoolAdvantage Petite applicators approved outside of China for the upper arm and inner 
thigh body areas.
In Canada, the Allergan CoolSculpting System is licensed (License #78510) and approved for:

Fat layer reduction through cold-assisted lipolysis

Minimizing pain and thermal injury during laser and dermatological treatments

Acting as a local anesthetic for procedures that induce minor local discomfort

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 14 of 70
CONFIDENTIAL
The CoolSculpting System can also provide localized thermal therapy (hot or cold) to minimize 
pain for post-traumatic and/or post-surgical pain and to temporarily relieve minor aches and 
pains and muscle spasms. The optional massage function can also be used for temporary:

Relief of minor muscle aches, pains, and spasms

Improvement in local circulation
Studies using CoolAdvantage applicators for the upper arms and inner thighs
4.1.1
There have been 2 clinical publications outlining the safety and efficacy of CoolAdvantage 
applicators for the upper arms. There have been no studies outlining the safety and efficacy of 
CoolAdvantage applicators for the inner thighs. However, there are 2 studies reporting the use of 
CoolFit, a legacy CoolSculpting applicator, for the inner thighs. The results of these studies are 
summarized below.
Rivers 2018 reported the efficacy and safety of using CoolAdvantage applicators in the upper 
arms of 15 subjects using clinical photography, ultrasound, caliper measurements, and subject 
satisfaction. In this single-center, open-label interventional study, subjects received simultaneous 
bilateral arm cryolipolysis treatments with up to two treatment cycles per arm conducted in a 
single session. Results were assessed 12 weeks after treatment. There was 83% correct 
identification (by a panel of 3 blinded physicians trained in dermatology or plastic surgery) of 
clinical photography before and after treatment. Ultrasound measured a mean fat layer reduction 
of 2.5 mm (SD = 2.4 mm, 95% CI = 1.6 to 3.3 mm) and caliper measurements demonstrated a 
mean fat layer reduction of 1.3 mm (SD = 1.42 mm, 95% CI = 0.6 to 2.1 mm) after cooling 
treatment. In addition, 87% of subjects were satisfied, 80% would recommend cryolipolysis to a 
friend, and 80% felt their appearance had improved after having the procedure. During treatment 
the average pain score was 1.3 ± 0.9; immediately after device removal pain was 1.4 ± 2.0, and 
prior to discharge it was 1.0 ± 1.2. At follow-up visits 1, 4, and 12 weeks post-treatment, all
subjects reported a pain score of 0. Clinical assessment of the treatment sites was performed
immediately post-treatment and at the follow-up visits. Immediately post-treatment, the most 
common AEs within the treatment area were numbness, erythema, and bruising. By the 4-week 
follow-up visit, all of these AEs had resolved except for mild numbness in the treatment zone 
reported by 73% of subjects. At the 12-week final visit, all AEs had resolved spontaneously. 
There were no reported device- and/or procedure-related complications, including paradoxical
adipose hyperplasia.
Carruthers 2017 reported the efficacy and safety of the prototype CoolCup (CoolAdvantage) 
applicator in the upper arms of 30 subjects using clinical photography and ultrasound. In this 
multi-center, open-label interventional study, each subject received one cooling cycle to each 
arm that was assessed 12 weeks after treatment. There was an overall 85.2% (p < 0.0001) correct 
identification of clinical photography by at least 2/3 of blinded reviewers trained in dermatology 
or plastic surgery. Ultrasound measured a mean fat layer reduction of 3.2 mm, with a SD of 
2.7 mm. The intra-treatment pain scores for all 60 arms treated were averaged and the overall 
average pain score was 1.0, with a SD of 1.2. By the 12-week post-treatment visit, all subjects 
reported a pain score of 0. Immediately after treatment, the most common side effects within the 
treatment area were erythema, edema, numbness, and tingling. By the 12-week post-treatment 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 15 of 70
CONFIDENTIAL
visit, all side effects had resolved without intervention except for some cases of numbness in the 
treatment area. The treatment area numbness for these subjects was not clinically significant, did 
not disrupt normal activities, and spontaneously resolved without intervention. Including the
aforementioned prolonged numbness, there were a total of 10 device- and/or procedure-related 
AEs. Four subjects reported prolonged numbness (bilateral numbness in 3 subjects, unilateral in 
1 subject) with a duration longer than 12 weeks. One subject reported bilateral mild erythema 
that resolved 15 days post treatment. One subject reported minor tingling in the fourth and fifth 
fingers of her left hand immediately after device removal, which resolved within approximately 
20 minutes post-treatment.
Zelickson 2015 reported the efficacy and safety of CoolFit applicators on the inner thighs of 
45 subjects. In this multi-center, open-label interventional study, each subject received a single 
treatment cycle to the inner thigh that was assessed at 8 and 16 weeks after treatment. Clinical 
photography taken at baseline and at 16 weeks was assessed by 3 blinded independent physicians. 
Before and after photography was correctly identified in 91% of cases. A statistically significant 
0.9 cm reduction of mean circumference was detected at 16 weeks compared to baseline 
(p < 0.005) and ultrasound measurements showed a mean fat layer reduction of 2.8 mm 
(95% CI = 2.23 to 3.27 mm, SD = 2.3 mm, range = + 3.4 mm to – 9.0 mm). At 16 weeks, subject
satisfaction was 93%, 89% would recommend the treatment to a friend, 91% were likely to have 
a second procedure, and 84% noticed visible fat reduction in their inner thighs after one 
treatment. All side effects were transient and typical, such as erythema, mild swelling, and 
numbness. The longest time to full resolution for each of these side effects was 8 days for 
erythema, 12 days for mild swelling, and 132 days for mild numbness. There were no SAEs
related to the device or procedure.
Boey 2014 reported the efficacy and safety of a prototype flat cup applicator (CoolFit) in the
inner thighs of 11 subjects. In this single-center, open-label pilot study, each subject received a 
single treatment cycle to the inner thigh that was assessed at 8, 16, and 24 weeks. The 
contralateral thigh was an untreated control. Clinical photography taken at baseline and at 
28 weeks was assessed by 2 blinded independent physicians and was correctly identified in 86% 
of cases. Normalized ultrasound measurements comparing baseline to 16 weeks post-treatment
demonstrated a 20% reduction following treatment. Participant surveys at 16 weeks revealed 
91% were satisfied and 82% felt inner thigh cryolipolysis was comfortable. Side effects in the 
treatment area, such as numbness and tenderness, were typical and self-resolving by the 8-week 
follow-up evaluation. No skin-related side effects were reported, such as blistering, persistent 
erythema, or hyperpigmentation.
CoolSculpting Studies in Asian Participants
4.1.2
It has been reported that 4 studies have assessed CoolSculpting in Asian participants 
(Putra 2019).
Suh 2018 reported the efficacy and safety of the CoolMini applicator applied to the submental 
space of 10 Korean subjects. In this single-center, open-label interventional study, each subject 
received 2 treatment cycles in one session that was assessed after 8 weeks. At 8 weeks, caliper 
measurement of the submental fat thickness reduced in 9 out of 10 participants, with an average 
reduction at 4 mm (23.2%). In ultrasound evaluation, there was a reduction of submental fat in 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 16 of 70
CONFIDENTIAL
9 subjects at an average of 35.2%. The side effects were transient and tolerable. All participants 
showed mild erythema and edema, but no reported incidences of purpura, pain, paresthesia, and 
post-inflammatory hyperpigmentation.
Wanitphakdeedecha 2015 reported the efficacy and safety of CoolFit applicators in the upper 
arms and inner thighs of 20 Thai female subjects. In this single-center, open-label interventional 
study, 17 subjects completed the study following a single CoolSculpting treatment to their arms
and/or inner thighs that were assessed after 3 and 6 months. There were average circumference 
reductions at the 3- and 6-month follow-up visits of 0.41 cm (0.87%) and 0.72 cm (1.52%),
respectively. Subjects satisfaction surveys showed that most of the subjects were rated to have 
1% to 25% improvement at the 3- and 6-month follow-up visits after treatment, respectively. 
There was no statistically significant difference between the satisfaction at the 3- and 6-month 
follow-ups (p = 0.835). Adverse reactions of 34 treatments included pain, erythema, dysesthesia, 
and purpura on the treated area. Intra-and post-procedural pain was described as mild to 
moderate by most of the subjects. The pain score was measured by visual analogue scale of 
0 to 10; the mean pain score rated by subjects was 7 (ranging from 1 to 10). Post-inflammatory 
hypopigmentation, scarring, and paradoxical adipocyte hyperplasia were not observed.
Lee 2013 reported the use of cryolipolysis to reduce fat tissue in the thighs of 14 premenopausal 
Korean subjects. In this single-center study, CoolSculpting was performed on the left inner thigh 
for 60 minutes using a Cooling Intensity Factor of -73 mW/cm2 with radiofrequency applied to 
the right inner thigh (control sham procedure). The primary endpoint was the difference in the
femoral amount measured by computerized tomography from baseline to 12 weeks after 
treatment. In this study there was an observed 19.5% reduction of fat tissue for CoolSculpting 
compared to 28.2% reduction for radiofrequency. No major AEs were noted; 4 of 14 subjects
experienced pain, whilst 3 of 14 participants reported moderate bruising. The authors concluded 
they could not show any difference in the reduction of fat following CoolSculpting or 
radiofrequency and postulated weight gain, inflammation post treatment and study design as 
postulated reasons for showing no difference.
Shek 2012 reported clinical effectiveness and participant satisfaction of a novel cryolipolysis 
device (ZELTIQ®) for body contouring after 1 treatment and after 2 treatments to the flanks and 
abdomen in a commercial setting. Twenty-one Chinese subjects received a single treatment 
lasting 60 minutes and 12 subjects received 2 treatments lasting 60 minutes each (an average of 3 
months apart). The thickness of fat at the treatment site was measured using a caliper and 
standardized clinical photos were taken at baseline and 2 months post-treatment. There was 
significant abdominal caliper improvement of 14.67% (p < 0.0001) from baseline in the first 
group of subjects and after both treatments in the second group of subjects; for the abdomen 
(14% - 1st treatment [p < 0.0001], 7.2% - 2nd treatment [p = 0.02%]); flanks (13.4% - 1st
treatment [p=0.003%], 4.3% - 2nd treatment [p=0.084%]). Eighty-one percent of subjects were 
rated to have moderate to good improvement. Subjectively, 80% felt satisfied to very satisfied, 
and the remaining were indifferent. Eighty-six percent would have considered non-invasive 
cryolipolysis performed on another part of their body and would consider recommending this 
treatment to family and friends.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 17 of 70
CONFIDENTIAL
4.2
Rationale
The current CoolSculpting applicators (CoolAdvantage family, CoolMini, and CoolSmooth Pro) 
are not cleared in China where the flanks and abdomen are the only approved body areas. This 
study, to be conducted in Canada, will collect meaningful clinical data for the use of 
CoolSculpting in participants of Chinese descent using CoolAdvantage and CoolAdvantage 
Petite applicators for the upper arms and inner thighs. Furthermore, it will help support a 
regulatory submission to the Chinese authorities where submissions are being planned to seek 
clearance for these applicators and extend the number of body area indications.
Benefit and Risks
4.2.1
4.2.1.1
Benefits
NIFR in the treatment area is anticipated to provide an aesthetic benefit and the use of this non-
invasive system will eliminate the need for an invasive procedure that requires anesthesia or 
recovery time.
4.2.1.2
Risks
Although this study presents minimal risks to the participant, there is the potential for some risk 
when any medical procedure is performed. 
Anticipated Device Effects
These are known effects of the CoolSculpting procedure, previously recorded in prior studies as 
transient and/or temporary effects related to the cold application and/or vacuum pressure inherent 
in the treatment. Anticipated effects of the device which will not be considered AEs include: 

inflammation of the subcutaneous fat layer, which is a desired effect of the procedure;

sensations of coldness, stinging, burning, pinching, or pressure associated with placement 
of the applicator and the initiation of the cold treatment;

known skin effects (eg, blanching; erythema, bruising, purpura, petechiae, swelling, 
discomfort, tenderness, or soreness at the treatment site, all mild to moderate in nature), 
which are temporary effects that resolve spontaneously shortly after the procedure; and

localized sensory changes (eg, numbness, tingling) at the treatment area spontaneously 
resolving without medical intervention within 12 weeks of the procedure.
If the severity of these anticipated effects causes disruption to the participant’s daily activities, 
then they will be evaluated as a potential adverse effect.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 18 of 70
CONFIDENTIAL
Potential Adverse Effects
Potential Adverse Effect
Description
Severe Bruising
The appearance of bruising (purple discoloration); purpura (purple colored spots 
or patches); or petechiae (pin point red dots) that is rated as severe by the 
investigator.
Prolonged Bruising
Bruising lasting longer than 1 month.
Severe Erythema
The appearance of erythema (redness) that is rated as severe by the investigator.
Prolonged Erythema
Erythema lasting longer than 2 weeks.
Severe Swelling
The appearance of swelling (edema) that is rated as severe by the investigator.
Prolonged Swelling
Swelling lasting longer than 1 month.
First Degree Burn
Skin damage from burns may be due to hot or cold. A first degree burn is 
superficial and causes local inflammation of the skin. The inflammation is 
characterized by pain, redness, and mild swelling. The skin may be very tender 
to touch.
Second Degree Burn
Second degree burns are deeper and, in addition to the pain, redness, and 
inflammation, there is also blistering of the skin. 
Third Degree Burn
Third degree burns are deeper still, involving all layers of the skin. Because the 
nerves and blood vessels are damaged, third degree burns appear white, 
leathery, and tend to be relatively painless.
Cold-induced Panniculitis
Severe inflammation which requires medical or surgical intervention.
Skin Pigment Changes
The appearance of hyperpigmentation or hypopigmentation in the treatment 
area.
Infection
Infection at the treatment site, diagnosed by a physician and requiring medical 
intervention.
Discomfort During Procedure
Discomfort reported during the procedure that is intolerable to the participant
and results in an interruption or discontinuation of the procedure
Discomfort Post Procedure
Significant discomfort, pain, cramping, tenderness, soreness, muscle spasm 
following the procedure which results in medical intervention (physician visit 
and/or prescription pain reliever)
Prolonged Sensory Alteration 
Post Procedure
Sensory changes (numbness, tingling, burning sensation) that are prolonged (ie, 
lasting longer than 12 weeks).
Sensory Alteration Requiring 
Medical Intervention
Sensory changes (pain, burning, stinging, hypersensitivity) with a severity 
warranting medical intervention.
Vasovagal Symptoms
The occurrence of symptoms of anxiety, light-headedness, dizziness, nausea, 
sweating, near syncope, or syncope (fainting).
Contour Irregularity
Significant indentation or contour irregularity in the treatment area that would 
require surgical intervention.
Allergic/Irritant Contact 
Dermatitis
Itchy rashes and skin peeling that may result from prolonged exposure to gel 
pad or applicator pressure
Subcutaneous Induration
Hardness within the treatment area, either as general firmness or discrete 
nodules.
Paradoxical Hyperplasia
Visibly enlarged tissue volume within the treatment area which may develop 2-
5 months after treatment. 
Hernia
Creation or exacerbation of hernia. Hernia is defined as a protrusion of an organ 
or the fascia of an organ through the wall of the cavity that normally contains it.
Treatment Area Demarcation
Treatment area demarcation: excessive fat removal in the treatment area causing 
unwanted indentation
Other
Any other untoward medical event determined by the investigator to be an 
adverse event, regardless of the relationship to the device or treatment.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 19 of 70
CONFIDENTIAL
5
STUDY OBJECTIVE AND ENDPOINTS
5.1
Objectives
The objective of this study is to evaluate the safety and effectiveness of the Allergan 
CoolSculpting system using CoolAdvantage and CoolAdvantage Petite applicators for NIFR of 
the upper arms and inner thighs in participants of Chinese descent.
5.2
Endpoints
Primary Endpoint:

Correct identification of baseline versus 12-week treatment images of the upper arms by at 
least two out of three blinded, independent reviewers. Success will be defined as at least 
75% correct identification of the pre-treatment images.
Secondary Endpoints:
1. Correct identification of baseline versus 12-week treatment images of the inner thighs by 
at least two out of three blinded, independent reviewers.
2. Participant response of ‘satisfied’ or ‘very satisfied’ for question 1 (overall satisfaction) on 
the following CoolSculpting participant questionnaires at the 12-week visit:
a.
Upper arms
b. Inner thighs
3. Fat reduction using caliper measurements at 12-weeks compared to baseline for the 
following areas:
a.
Upper arms
b. Inner thighs
Safety Endpoints:

AEs, including SAEs; and ADEs, including SADEs. 
 
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 20 of 70
CONFIDENTIAL
6
INVESTIGATIONAL PLAN
6.1
Overall Study Design and Plan: Description
Study MED-MA-PLS-0633 is a multi-center, prospective, open-label, nonrandomized, 
interventional cohort, medical device post marketing study. The Schedule of Assessments is 
provided in Table 1.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 21 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 22 of 70
CONFIDENTIAL
6.2
Discussion of Study Design
The background and rationale that led to the study design are described in Section 4.1 and 
Section 4.2.
6.3
Selection of Study Population
Number of Planned Participants
6.3.1
Approximately 42 participants will be enrolled at approximately 2-3 sites.
Refer to the statistical considerations on which the numbers are based in Section 9.1.
Inclusion Criteria
6.3.2
To be eligible for study entry, participants must satisfy all of the following criteria:
1. Participant (healthy volunteers) has read and signed the study written ICF.
2. Male or female participant ≥ 18 years of 1st or 2nd generation, non-mixed race, Chinese 
descent.
3. Participant has clearly visible and palpable fat on the left and right lower aspects of the 
upper arms and/or left and right inner thighs, which in the investigator’s opinion is 
appropriate and may benefit from the treatment.
4. Participant has not had weight change fluctuations exceeding 4.5 kg (or 5% of body 
weight) in the preceding month.
5. Participant has a BMI of ≥18.5 to ≤30. A BMI is defined as weight in kilograms divided 
by height in meters squared (kg/m2). 
6. Participant agrees to maintain weight (ie, within 5% of body weight) by not making any 
changes in diet or exercise routine during the course of the study.
7. Participant agrees to have photographs taken of the treatment area(s) during the scheduled 
time periods.
 
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 23 of 70
CONFIDENTIAL
Exclusion Criteria
6.3.3
Participants will be excluded from the study if one or more of the following criteria are 
applicable:
1. Participant has a history of an invasive fat reduction procedure (eg, liposuction, surgery, 
lipolytic agents, etc), or implants in or immediately adjacent to the area of intended 
treatment.
2. Participant has a history of prior surgery or scar tissue on the arms and/or inner thighs 
related to the area being considered for treatment.
3. Participant has a known history of cryoglobulinemia, cold urticaria, cold agglutinin 
disease, or paroxysmal cold hemoglobinuria.
4. Participant has a known sensitivity to cold or has any condition with a known response to 
cold exposure that limits blood flow to the skin, such as cold urticaria, Raynaud’s disease, 
or Chilblains (pernio).
5. Participant with a clinically significant bleeding disorder, or concomitant use of oral or 
subcutaneous anticoagulants, or is taking any medication that in the investigator’s opinion 
may significantly increase the participant’s risk of bruising.
6. Participant with a history of carpal tunnel syndrome, compartment syndrome, or deep vein 
thrombosis in the upper or lower extremities.
7. Participant is currently taking or has taken diet pills or weight control supplements within 
the past 6 months.
8. Participant has any dermatological conditions, such as moderate to excessive skin laxity, 
infection, open wound, or scars in the location of the treatment sites that may interfere 
with the treatment or evaluation (stretch marks are not an exclusion).
9. Participant has an active implanted device such as a pacemaker, defibrillator, drug 
delivery system, or any other metal-containing implant within or adjacent to the area 
being considered for treatment.
10. Participant is pregnant or intending to become pregnant in the next 3 months.
11. Participant is lactating or has been lactating in the past 6 months.
12. Participant is unable or unwilling to comply with the study requirements.
13. Participant is currently enrolled in a clinical study of any unapproved investigational 
device, investigational product, or any other type of medical research judged not to be 
scientifically or medically compatible with this study.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 24 of 70
CONFIDENTIAL
14. Participant has any other condition or laboratory value that would, in the professional 
opinion of the investigator, potentially affect the participant’s response or the integrity of 
the data or would pose an unacceptable risk to the participant.
15. Participant has had a NIFR and/or body contouring procedure in the area(s) of intended 
treatment within the past 12 months.
16. Participant needs to administer, or has a known history of subcutaneous injections, into 
the area(s) of intended treatment (eg, cortisone, heparin, insulin) within the past 6 months.
17. Participant with known sensitivity or allergy to fructose, glycerin, isopropyl alcohol, or 
propylene glycol.
18. Participant with impaired peripheral circulation in the area to be treated.
19. Participant with neuropathic disorders such as post-herpetic neuralgia or diabetic 
neuropathy.
20. Participant with impaired skin sensation.
21. Participant with a history of hernia in or adjacent to the treatment area(s) site.
22. Participant with a skin condition such as eczema, dermatitis, or rashes in the area to be 
treated.
23. Participant diagnosed with a systemic fibrosing disease or fibrosis in the area intended or 
adjacent to the area to be treated.
Removal of Participants from Therapy or Assessments
6.3.4
Notification of early participant discontinuation from the study and the reason for 
discontinuation will be provided to the sponsor and will be clearly documented on the 
appropriate CRF.
Reasons for discontinuation from the study may include the following:

Completed

Other

Physician decision

Protocol deviation

Screen failure

Site terminated by sponsor

Study terminated by sponsor

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 25 of 70
CONFIDENTIAL

Technical problems

Withdrawal by subject
Participants who do not comply with the protocol or who withdraw consent will not be replaced. 
Participants who stop study treatment for any other reason will not be replaced. Participants are 
free to withdraw from the study at any time without providing reason(s) for withdrawal and 
without prejudice to further treatment. The reason(s) for withdrawal will be documented in the 
CRF.
Participants withdrawing from the study will be encouraged to complete the same final 
evaluations as participants completing the study according to this protocol, particularly safety 
evaluations. The aim is to record data in the same way as for participants who completed the 
study.
Reasonable efforts will be made to contact participants who are lost to follow-up. These efforts 
must be documented in the participant’s file. 
The sponsor has the right to terminate the study at any time in case of SAEs or if special 
circumstances concerning the CoolSculpting procedure or the company occur, making further 
treatment of participants impossible. In this event, the investigator(s) will be informed of the 
reason for study termination.
Pregnancy
Female participants will be instructed that known or suspected pregnancy occurring during the 
study should be confirmed and reported to the investigator, who fills out a provided pregnancy 
surveillance form. The form needs to be sent to the sponsor within 24 hours of awareness of a 
confirmed pregnancy to the following email address: 
CoolSculptingProductSurveillance@allergan.com
Once pregnancy is confirmed, the participant will be immediately withdrawn from the study. 
Upon discontinuation from the study, only those procedures that would not expose the 
participant to undue risk will be performed. The investigator should also be notified of 
pregnancy occurring during the study but confirmed after completion of the study. In the event 
that a participant is subsequently found to be pregnant after inclusion in the study, any pregnancy 
will be followed to term, and the status of mother and child will be reported to the sponsor after 
delivery using the second page of the pregnancy surveillance form. 
Full details will be recorded on the withdrawal page of the CRF.
6.4
CoolSculpting System
CoolSculpting Description 
6.4.1
Participants will undergo a CoolSculpting treatment in an outpatient clinical setting. A treatment 
is comprised of timed segments of cooling. Treatments will be administered according to the 
User Manual CoolSculpting System that has been prepared for specific countries. The 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 26 of 70
CONFIDENTIAL
CoolSculpting System, also labelled as the ZELTIQ System or the ZELTIQ Breeze System, is a 
non-invasive cooling device that applies controlled cooling to a treatment site on the 
participant’s skin.
Identity of CoolSculpting System
6.4.2
The CoolSculpting System is comprised of a control unit, a surface or vacuum applicator, and 
supplies such as cards, foam borders, gel pads, liners, pre-treatment skin wipes, and securement 
systems. The applicators, foam borders, gel, gel pads, liners, pre-treatment skin wipes, and 
securement systems are participant-applied parts.
During a treatment, the operator applies a gel/gel pad and applicator to the participant’s skin. The 
vacuum applicator draws tissue into the applicator cup and holds the tissue against the cooling 
surfaces of the applicator. The operator starts the treatment. Sensors in the cooling surfaces of 
the applicator monitor the skin surface, providing feedback that controls the rate of heat flux. 
The gel/gel pad protects the skin by providing thermal coupling at the interface between the 
cooling surfaces of the applicator and the skin. The card provides cycles and profiles for use with 
the system.
The CoolSculpting System operates at temperatures below 0°C, which can freeze tissue. 
Therefore, the system monitors tissue during cooling and employs multiple safety features, 
including the Freeze Detect system, to minimize the risk of damage to tissue. In spite of these 
multiple safety features, on rare occasions, a possible freeze condition may occur that can be 
detected by the Freeze Detect System.
The Freeze Detect system is comprised of several features, including thermal sensors and 
proprietary algorithmic software. Freeze Detect is an integral part of the CoolSculpting System 
and is automatically employed when a treatment is initiated. When the Freeze Detect system 
detects a possible freeze condition, it stops the treatment and displays a Z409 message. If this 
message is received, remove the applicator and gel pad or gel, and assess the tissue before taking 
further action. The current recommended practice is to wait at least 24 hours before retreating the 
area relating to a Z409 error message. Failure to follow instructions could result in injury to the 
participant, including first- or second-degree burns. Second-degree burns or complications of 
second-degree burns may result in hyperpigmentation.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 27 of 70
CONFIDENTIAL
6.4.2.1
Control Unit
Control Unit - Front View
Components - Front View
1. Rail: When the applicator is resting on top of the control unit, the rail helps keep the 
applicator in place. In addition, the rail is used as a handle to move the system.
2. Vents: Vents provide airflow that reduces heat build-up inside the control unit. Ensure all 
vents are free from obstructions when the control unit is in operation.
3. Drawer: The drawer provides storage space for supplies and user documentation.
4. Casters and Locks: The control unit has four casters that swivel. Each caster has a lock. 
Always engage the locks on all four casters before you use the control unit.
5. Screen: The screen displays system controls, information about the status of the system, 
information about the treatment, and messages for the operator.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 28 of 70
CONFIDENTIAL
Control Unit - Rear View
Components: Control Unit, Rear View
1. Rail: When the applicator is resting on top of the control unit, the rail helps keep the 
applicator in place. In addition, the rail is used as a handle to move the system.
2. Vents: Vents provide airflow that reduces heat build-up inside the control unit. Ensure that 
all vents are free from obstructions when the control unit is in operation.
3. Latches: The latches lock the upper and lower modules of the control unit together.
4. Antenna: The antenna and data modem send data to Allergan (availability and use of the 
data modem are subject to regional limitations).
5. Casters and locks: The control unit has four casters that swivel. Each caster has a lock. 
Always engage the locks on all four casters before you use the control unit.
6. Cleats: When the power cord is not in use, wrap it loosely around the cleats.
7. Chiller tank cap: The chiller tank cap provides access to the chiller tank for checking the 
coolant level and adding coolant.
8. Support Arm: Drape the applicator cable over the support arm to minimize drag on the 
connections and to keep the cable out of your way. Use the Velcro ® straps to secure the 
cable to the support arm.
6.4.2.2
Applicator
The applicator delivers controlled cooling to the treatment site.
The applicator consists of the applicator connector, the applicator cable, and the applicator head.
The applicator is used with supplies provided by Allergan.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 29 of 70
CONFIDENTIAL
Packaging and Labelling
6.4.3
Clinical study materials will be labelled according to the country’s regulatory requirements.
Method of Assigning Participants to Treatment Groups
6.4.4
At screening, after the participant has signed the ICF, the participant will be assigned a 
participant number sequentially based on the order in which the participant is screened into the 
study. This participant number will serve as the participant identification number on all study 
documents.
Blinding
6.4.5
This is an open-label study. Blinding will only be employed for photograph review by an 
independent panel of physician reviewers with expertise in the areas of dermatology and/or 
plastic surgery.
Prior and Concomitant Therapy
6.4.6
All concomitant therapies that are part of routine care are allowed and can be used during the 
study. Diet pills or weight control supplements are not permitted (see exclusion criterion # 7 in 
Section 6.3.3).
Treatment Compliance
6.4.7
The study investigators are responsible for performing the study in compliance with the protocol. 
Non-adherence to the protocol is to be classified as a protocol violation, protocol deviation, or 
protocol exemption, as defined below.
Protocol Violation
A violation is any non-adherence to the protocol that may result in significant additional risk to 
the participant (eg, enrollment of a participant who does not meet the study criteria). A protocol 
violation can also be an event of non-adherence to GCPs that may impact participant safety (eg, 
failure to obtain proper consent before performing study procedures). Violations should be 
reported to the study sponsor and the IRB within 5 working days if they occur.
Protocol Deviation
A deviation is any non-adherence to study procedures that does not result in additional risk to the 
participant (eg, participant missed a visit). Protocol deviations are not required to be reported to 
the IRB; however, they must be recorded on the study CRFs and may be reported and reviewed 
in conjunction with the progress report as part of the annual review process.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 30 of 70
CONFIDENTIAL
7
TIMING OF STUDY PROCEDURES
Participants will provide written informed consent before any study-related procedures are 
performed.
The planned study assessments are provided in Section 6.1.1.
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 31 of 70
CONFIDENTIAL
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 32 of 70
CONFIDENTIAL
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 33 of 70
CONFIDENTIAL
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 34 of 70
CONFIDENTIAL
8
EFFECTIVENESS AND SAFETY ASSESSMENTS
The planned schedule of assessments is provided in Section 6.1.1.
8.1
Effectiveness Assessments
Photography
8.1.1
A series of baseline and follow-up photographs of the treatment areas will be taken using 
standardized set up, lighting, and camera settings to ensure consistency. The participants’ faces 
will not be on the photographs. No other identifiable participant information will be recorded on 
the photographs. Where participant identifiable markings are seen within the treatment area, the
images containing these markings will not be used for the purpose of publications but kept as 
part of the study record in the TMF. The photographs may be cropped or re-sized for comparison 
purposes but otherwise will not be re-touched or altered in any way. Image files will be stored 
electronically by Allergan in addition to Quantificare and indexed by participant identifier. 
Copies of participant photographic data will be filed at the clinical site. 
Photos will be reviewed by a blinded independent panel of physician reviewers with expertise in 
the areas of dermatology and/or plastic surgery. All photographs will be blinded by removing the 
participant identification and dates of the photographs. The reviewers will be presented with two 
series of photographs for each treatment area, the pre-treatment and the post-treatment series, 
and asked to select the series representing the pre-treatment photographs. The order in which the 
photographs are presented will be randomized by participant. The order in which the pre- and 
post-treatment series are presented will also be randomized. The reviewers will be asked to select 
the baseline photograph series for each treatment area and record their data on individual data 
collection forms provided by the Sponsor.
Participant Satisfaction
8.1.2
Participant satisfaction data will be collected via written questionnaires at the final 12-week 
follow-up visit. These questionnaires have been developed based on questions used in previous 
CoolSculpting studies and modified to pertain to specific body areas treated (upper arms and 
inner thighs). One or two questionnaires will be provided depending on the body areas treated 
(upper arms and/or inner thighs). For the upper arm participant satisfaction questionnaire, see 
Section 15.3.1. For the inner thigh participant satisfaction questionnaire, see Section 15.3.2.
Caliper Measurement
8.1.3
Caliper measurements of the treatment areas will be taken at pre-treatment and at 12-weeks post 
final treatment. After the treatment area is identified and marked, the thickness of the fat layer 
will be measured using a caliper at the middle of the fat bulge. For each treatment area, 3
measurements will be taken and recorded. The average of the three measurements will be 
calculated. The location of where measurements are taken will be recorded on a transparency 
sheet or equivalent, along with reference points using the participant’s body landmarks (such as a 
mole, skin pigmentation, etc). This transparency may be used at the post treatment visit to locate 
the measurement sites. In addition, to further ensure the quality and consistency of the 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 35 of 70
CONFIDENTIAL
measurements, the same staff member should perform the caliper measurements for each 
participant. For further details on caliper measurements, please see Section 15.4. 
8.2
Safety Assessments
Throughout the course of the study, all AEs will be monitored and reported on an AE CRF, 
including seriousness, severity, action taken, and relationship to study treatment. If AEs occur, 
the first concern will be the safety of the study participants.
Safety will be monitored by documentation of AEs and clinical assessment of the treatment sites. 
Post-treatment sensory changes outside of treatment areas will also be documented and assessed.
Adverse Events
8.2.1
Throughout the course of the study, all AEs will be reported and monitored on an AE CRF, 
including event name, duration, seriousness, relatedness, severity, action taken, and outcome. If 
AEs occur, the first concern will be the safety of the study participants. AEs and device 
deficiencies are to be recorded on the corresponding CRF for the participant upon the site 
becoming aware of said event. Additionally, SAEs and UADEs will be reported using SAE 
forms within 24 hr of awareness.
AEs will be collected throughout the study once there is a signed ICF. At each visit, the 
investigator or designated study staff will solicit and assess the participant for AEs. Previously 
recorded AEs and changes in therapy/concomitant medications are to be updated as necessary. 
All reportable AEs and clinically significant abnormal laboratory findings will be documented on 
the appropriate CRF.
Adverse Event Definition
An AE is defined in accordance with ISO 14155 as any untoward medical occurrence, 
unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) 
in participants, users, or other persons, if related to the investigational medical device. This 
definition includes events related to the investigational medical device or comparator and events 
related to the procedures involved. Disease signs and symptoms that existed before the study 
treatment are not considered AEs unless the condition recurs after the participant has recovered 
from the pre-existing condition or the condition worsens in intensity or frequency during the 
study.
AEs will be monitored throughout the study once the participant has signed the ICF. At each 
post-baseline visit, the investigator will begin querying for AEs by asking each participant a 
general, non-directed question such as “Have you had any changes to your condition since your 
last visit?” Previous AEs and changes in therapy/concomitant medications are to be updated. 
Directed questioning and examination will then be done as appropriate. All reportable AEs and 
clinically significant abnormal laboratory findings will be documented on the appropriate eCRF.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 36 of 70
CONFIDENTIAL
Adverse Device Event
An ADE is defined in accordance with ISO 14155 as “an adverse event related to the use of an 
investigational medical device.” This definition includes any AEs resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device as well as any event resulting from use error 
(per ISO 62366) or from intentional misuse of the investigational medical device. 
Device Deficiency or Complaints
A device deficiency is defined in accordance with ISO 14155 as inadequacy of a medical device 
including issues with respect to its identity, quality, durability, reliability, safety, or performance. 
Device deficiencies include malfunctions, use errors, and inadequate labelling.
If a device deficiency occurs, the investigator will notify Allergan using the CRF. Device 
deficiencies shall be documented throughout the study and appropriately managed by Allergan. 
The Clinical Trial Site will enter all the information regarding device deficiency into the 
appropriate CRFs. Device deficiencies associated with AEs will also require completion of SAE 
forms. Allergan shall review all device deficiencies and determine and document in writing 
whether they could have led to a SADE. These shall be reported to the regulatory authorities and 
IRBs as required by Federal regulations.
Assessment of Severity
Severity is a clinical determination of the intensity of an AE. The severity assessment for a 
clinical AE will be assigned a category by the investigator as follows:
Mild
An AE that is easily tolerated by the participant, causes minimal discomfort, may 
require only minimal treatment and does not interfere with everyday activities.
Moderate
An AE that is sufficiently discomforting to interfere with normal everyday 
activities; intervention may be needed, but poses no significant or permanent risk 
of harm.
Severe
An AE that prevents normal everyday activities; treatment or other intervention 
usually needed.
If there is a change in severity of an AE, it must be recorded as a separate event.
Assessment of Causality
Relationship to a device refers to a determination of the relationship (if any) between an AE and 
the device. A causal relationship is present if the investigator determines that there is a 
reasonable possibility that the AE may have been caused by the device.
An AE could be considered procedure-related when, in the judgment of the investigator, it is 
reasonable to believe that the event is associated with the procedure, regardless of the 
relationship to the study device. Procedure-related causes that contribute to the occurrence of the 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 37 of 70
CONFIDENTIAL
event can be attributed to other products, surgical techniques, or medications required 
specifically for the procedure.
Every effort will be made by the investigator to assess the relationship of the AE, if any, to the 
device and/or study procedure. Causality should be assessed using the categories presented in the 
following table:
Not related
Clinical event of which the relationship to the device and/or procedure 
can be excluded, such as if the event has an incompatible time 
relationship to study procedure and/or use of the device, involves a 
body part or organ not expected to be affected by the device or 
procedure, could be explained by underlying disease or other drugs or 
chemicals or is incontrovertibly not related to the study device, and is 
not due to use error.
Unlikely
Clinical event whose time relationship to use of the device and/or study 
procedure makes a causal connection improbable, but that could 
plausibly be explained by underlying disease or other drugs or 
chemicals.
Possible
Clinical event with a reasonable time relationship to the use of the 
device and/or study procedure, but that could also be explained by 
concurrent disease or other drugs or chemicals. Cases where
relatedness cannot be assessed or no information has been obtained 
should also be classified as possible.
Probable
Clinical event with a reasonable time relationship to the use of the 
device and/or study procedure, and is unlikely to be attributed to 
concurrent disease or other drugs or chemicals.
Causal relationship
Clinical event with plausible time relationship to the use of the device 
and/or study procedure, is a known side effect of the product category 
the device belongs to or of similar devices and procedures; follows a 
known response pattern to the medical device; involves a body-site or 
organ that the device or procedures are applied to and/or influence; 
harm is due to error in use, and that cannot be explained by concurrent 
disease or other drugs or chemicals.
Follow-up of Adverse Events
All investigators should follow up with participants with AEs until the event is resolved or until, 
in the opinion of the investigator, the event is stabilized or determined to be chronic. Details of 
AE resolution must be documented in the CRF.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 38 of 70
CONFIDENTIAL
Documentation and Reporting of Adverse Events
AEs should be reported and documented in accordance with the procedures outlined below. All 
AEs occurring during the study must be documented on the relevant CRF pages. The following 
data should be documented for each AE in the appropriate CRF fields:

Description of the symptom event.

Classification of ‘serious’ or ‘not serious.’

Severity.

Date of first occurrence and date of resolution (if applicable).

Action taken.

Causal relationship.

Outcome of event.
8.2.1.1
Serious Adverse Events
Serious Adverse Event Definition
An SAE is defined as an AE that: 

led to death

led to serious deterioration in the health of the participant, that either resulted in
o
a life-threatening illness or injury; or
o
a permanent impairment of a body structure or a body function, or
o
in-patient or prolonged hospitalization; or
o
medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function; or
o
if a participant becomes pregnant, then spontaneous abortion, fetal distress, fetal 
death, or a congenital abnormality or birth defect is considered an SAE
In addition, medical and scientific judgment is required to decide if prompt notification is 
required in situations other than those defined for SAEs above. This may include any event that 
the investigator regards as serious that did not strictly meet the criteria above but may have 
jeopardized the participant or required intervention to prevent one of the outcomes listed above, 
or that would suggest any significant hazard, contraindication, side effect, or precaution that may 
be associated with the use of the investigational product.
Serious Adverse Device Effect (SADE)
All device or surgical related SAEs must be entered into the EDC system within 24 hours of 
being notified of the event. The sponsor will be notified by EDC system once the SAE electronic 
form has been submitted.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 39 of 70
CONFIDENTIAL

The relationship of the clinical event to the devices and procedure should be reported on 
the Form and will be determined by the investigator.

Following evaluation of each SAE, the responsible ethics committee will be notified as 
appropriate based on national regulations.

All SAEs that occur from the time the ICF is signed through to their final study visit must 
be reported to the sponsor. In addition to entering the information into the EDC system, 
the investigator must:

Notify the sponsor immediately (within 24 hours) by emailing the Allegan Product 
Surveillance team at: CoolSculptingProductSurveillance@allergan.com
The following SAE information should be provided:

Description of the symptom event (including treatment dates, areas treated, event 
description, etc)

Applicator(s) and Serial Number used during treatment

Classification of ‘serious’ or ‘not serious’

Severity

Date of first occurrence and date of resolution (if applicable)

Action taken

Causal relationship

Outcome of event: report as much information within 24 hours regardless of the amount 
of information available, although the investigator is expected to provide as much 
information as possible.
Obtain and maintain in his/her files all pertinent medical records, information, and medical 
judgments from colleagues who assisted in the treatment and follow-up of the participant.
Provide the sponsor with a complete, written case history (AE report form) that includes a 
statement as to whether the event was or was not related to the use of the investigational device 
or procedure.
The sponsor (or its representative) will report all SAEs associated with the use of the study 
device to the regulatory agencies (Ethics Committee, Competent Authorities) as appropriate 
according to relevant standard operating procedures and to the national laws of the country 
where the trial is performed.
In every SAE, appropriate measures should be taken to treat/resolve and monitor the participant. 
The investigator should keep Allergan closely informed of the progress as related to the SAE. 
Any participants who are withdrawn from the study due to an AE shall still be followed until the 
outcome is resolved.
Details of the procedures to be followed if a pregnancy occurs are provided in Section 6.3.4.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 40 of 70
CONFIDENTIAL
8.2.1.2
Unanticipated Serious Adverse Device Effect 
Unanticipated Serious Adverse Device Effect Definition
An unanticipated serious ADE is a SADE effect that by its nature, incidence, severity, or
outcome has not been identified in the current version of the risk analysis report. 
Warnings and Precautions 
8.2.2
Unauthorized modification or repair of the control unit, its components, or supplies may result in 
unsafe conditions and/or impaired performance. No modification of this equipment is allowed 
without express authorization from Allergan. Any unauthorized modification or repair will void 
the warranty.
CoolSculpting System use has not been studied in children, those who are pregnant or lactating, 
or who have:

Known sensitivity to cold such as cold urticaria, Raynaud’s disease, or Chilblains 
(pernio)

Known sensitivity or allergy to fructose, glycerin, isopropyl alcohol, or propylene glycol

Impaired peripheral circulation in the area to be treated

Neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy

Impaired skin sensation

Open or infected wounds

Bleeding disorders or concomitant use of blood thinners

Recent surgery or scar tissue in the area to be treated

Hernia in or adjacent to the treatment site

Skin conditions such as eczema, dermatitis, or rashes in the area to be treated
Other Laboratory Variables
8.2.3
Screening for pregnancy will be performed (urine β-HCG at the Screening and Treatment visits).
 
 
 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 41 of 70
CONFIDENTIAL
8.3
Serious Adverse Event and Unanticipated Adverse Device Effect Reporting
SAEs and UADEs must be reported within 24 hours of knowledge of the event to the Sponsor at 
the following email address:
CoolSculptingProductSurveillance@allergan.com
A full reporting of the event shall be provided within 2 working days of the event. The Sponsor 
is then responsible for notifying the IRB, as required.
8.4
Data Safety Monitoring Board
Not applicable.
Appropriateness of Measurements
8.4.1
The effectiveness and safety assessments planned for this study are widely used and generally 
recognized as reliable, accurate, and relevant.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 42 of 70
CONFIDENTIAL
9
STATISTICAL METHODS
The SAP will be developed and finalized before database lock and will describe the participant 
populations to be included in the analyses and procedures for accounting for missing, unused, 
and spurious data. This section is a summary of the planned statistical analyses.
Data will be summarized based on the nature of the data. Categorical (eg, gender, independent 
photographic review) data will be tabulated by category. The mean, standard error, maximum, 
and minimum will be tabulated for continuous data (eg, age). The significance level will be 
two-sided 0.05 for all statistical tests.
9.1
Determination of Sample Size
In this study, both arms and thighs will be evaluated by independent raters. The independent 
raters’ evaluations will be combined into one clinical judgement on each arm and thigh. The 
evaluations on arms and thighs will be considered as independent.
Rivers 2018 described that the rate of correct identification was 83%. Using 75% as the lower 
bound of the 95% CI, the ½-width of the 95% CI will be 8%.
Based on these assumptions, we will need 60 evaluable arms or 32 evaluable participants for the 
arm evaluations with the assumption that less than 10% of participants have only one arm 
evaluation available.  The same number of participants for thigh evaluations will be needed.
With an assumption that only 80% of all subjects will have both arms and thighs treated, we will 
need 38 evaluable participants in total for the study. Adding a 10% attrition rate, we will need to 
enroll 42 participants in the study.
9.2
Populations for Analyses
1. PP population: The PP population will consist of all treated participants followed for 12 
weeks and with weight change of no more than 5% of total body weight at the time the 
12-week images are taken. Because a weight change of more than 5% will affect the 
images, the primary effectiveness analysis will be performed based on this study 
population. Participants who do not complete treatment on the upper arms and/or inner 
thighs will not be included in the effectiveness analyses.
2. AT population: The AT population will consist of all treated participants regardless of 
weight change, etc.
3. Safety population: The safety population will consist of all the treated participants with at 
least one safety evaluation after the treatment. This population should be identical to the 
AT population. All safety data analyses will be performed based on the safety population.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 43 of 70
CONFIDENTIAL
9.3
Statistical Analyses
Disposition, Baseline and Study Information
9.3.1
In general, disposition data, participant baseline and characteristics data, and concomitant 
therapy data will be summarized descriptively. The categorical variables will be presented with 
number and proportion while the continuous variables will be presented with mean, SD, median, 
minimum, and maximum.
9.3.1.1
Participant Disposition
The number of participants who have enrolled into the study, the number and percentage of 
participants who have had the procedure, the number and percentage of participants who have 
had all follow-up visits, and the number of participants who discontinued and the reasons for 
discontinuation will be summarized.
9.3.1.2
Participant Baseline and Characteristics
The demographics (age, sex, race [including determination of 1st or 2nd generation Chinese 
descent]) of participants will be summarized. 
The summary on height, weight, and BMI will be also provided. The number and percentage of 
participants by BMI category (normal 18.5 to 25, overweight 25 to 30) will also be provided.
9.3.1.3
Concomitant Therapy 
The concomitant therapy (drug and/or procedure) that a participant has during the study will be 
recorded and summarized.
9.3.1.4
Treatment Compliance 
The treatment compliance will not be applicable in this study.
Effectiveness Analyses
9.3.2
The primary effectiveness analysis will be based on the PP population.
9.3.2.1
Primary Effectiveness Analysis
The number and proportion of participants with correct identification of baseline vs 12-week 
images of the upper arms by at least two out of three blinded, independent reviewers and the
corresponding 95% CI of the proportion of participants with correct identification will be 
summarized.
9.3.2.2
Secondary Analyses
The number and proportion of participants with correct identification of baseline vs 12-week 
images of the inner thighs by at least two out of three blinded, independent reviewers and the 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 44 of 70
CONFIDENTIAL
corresponding 95% CI of the proportion of participants with correct identification will be 
summarized.
Participants who have reported ‘Very satisfied’ or ‘Satisfied’ on each of the CoolSculpting 
participant questionnaires (upper arms and inner thighs) for question #1 (overall satisfaction) will 
be categorized as ‘Satisfied.’ The numbers and proportions will be summarized and the 95% CI 
of the proportions will be provided.
Fat reduction at 12 weeks compared to baseline will be summarized descriptively.
 
Safety Analyses
9.3.3
The numbers and proportions of participants with AEs, SAEs, ADEs, and SADEs will be 
summarized. The numbers and proportions of participant-reported pain scores (0 to 10 scale) will 
be summarized.
9.3.3.1
Subgroup Analyses
Subgroup analyses will be documented in the SAP.
Interim Analyses
9.3.4
No interim analyses are planned for this study.
9.4
Protocol Deviations
Major protocol deviations will be determined before database lock. Details will be outlined in the 
SAP.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 45 of 70
CONFIDENTIAL
10 QUALITY ASSURANCE AND QUALITY CONTROL
10.1 Audit and Inspection
Study centers and study documentation may be subject to Quality Assurance audit during the 
course of the study by the sponsor or its nominated representative. In addition, inspections may 
be conducted by regulatory authorities at their discretion
10.2 Monitoring
Data for each participant will be recorded on a CRF. Data collection must be completed for each 
participant who signs an ICF and is administered study treatment.
In accordance with current GCP, the study monitor will carry out source document verification at 
regular intervals to ensure that the data collected in the CRF are accurate and reliable. 
The investigator must permit the monitor, the independent ethics committee (IEC)/IRB, the 
sponsor’s internal auditors, and representatives from regulatory authority’s direct access to all 
study-related documents and pertinent hospital or medical records for confirmation of data 
contained within the CRFs
10.3 Data Management and Coding
The sponsor or sponsor’s agent will be responsible for activities associated with the data 
management of this study. This will include setting up a relevant database and data transfer 
mechanisms, along with appropriate validation of data and resolution of queries. Data generated 
within this clinical study will be handled according to the relevant standard operating procedures 
of the data management and biostatistics departments of sponsor or agent.
Study centers will enter data directly into an EDC system by completing the CRF via a secure 
internet connection. Data entered into the eCRF must be verifiable against source documents at 
the study center. Data to be recorded directly on the eCRF will be identified and the eCRF will 
be considered the source document. Any changes to the data entered into the EDC system will be 
recorded in the audit trail and will be FDA CFR 21 Part 11 compliant.
Missing or inconsistent data will be queried in writing to the investigator for clarification. 
Subsequent modifications to the database will be documented.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 46 of 70
CONFIDENTIAL
11 RECORDS AND SUPPLIES
11.1 Device Accountability
Not applicable.
11.2 Financing and Insurance
Financing and insurance of this study will be outlined in a separate agreement between the 
sponsor and investigator’s site.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 47 of 70
CONFIDENTIAL
12 ETHICS
12.1 Independent Ethics Committee or Institutional Review Board
Before initiation of the study at each study center, the protocol, the ICF, other written material 
given to the participants, and any other relevant study documentation will be submitted to the 
appropriate IEC/IRB. Written approval of the study and all relevant study information must be 
obtained before the study center can be initiated. Any necessary extensions or renewals of 
IEC/IRB approval must be obtained for changes to the study such as amendments to the protocol, 
the ICF, or other study documentation. The written approval of the IEC/IRB together with the 
approved ICF must be filed in the study files.
The investigator will report promptly to the IEC/IRB any new information that may adversely 
affect the safety of the participants or the conduct of the study. The investigator will submit 
written summaries of the study status to the IEC/IRB as required. On completion of the study, 
the IEC/IRB will be notified that the study has ended.
12.2 Ethical Conduct of the Study
The investigator(s) and all parties involved in this study should conduct the study in adherence to 
the ethical principles based on the Declaration of Helsinki, GCP, and the applicable national and 
local laws and regulatory requirements.
12.3 Informed Consent
The process of obtaining informed consent must be in accordance with applicable regulatory 
requirement(s) and must adhere to GCP.
The investigator is responsible for ensuring that no participant undergoes any study-related 
examination or activity before that participant has given written informed consent to participate 
in the study.
The investigator or designated personnel will inform the participant of the objectives, methods, 
anticipated benefits, and potential risks and inconveniences of the study. The participant should 
be given every opportunity to ask for clarification of any points s/he does not understand and, if 
necessary, ask for more information. At the end of the interview, the participant will be given 
ample time to consider the study. Participants will be required to sign and date the ICF. After 
signatures are obtained, the ICF will be kept and archived by the investigator in the investigator’s 
study file. A signed and dated copy of the participant ICF will be provided to the participant or 
their authorized representative.
It should be emphasized that the participant may refuse to enter the study or to withdraw from 
the study at any time, without consequences for their further care or penalty or loss of benefits to 
which the participant is otherwise entitled. Participants who refuse to give or who withdraw 
written informed consent should not be included or continue in the study.
If new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study, a new ICF will be approved by the IEC(s)/IRB(s). The study 

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 48 of 70
CONFIDENTIAL
participants will be informed about this new information and reconsent will be obtained.
12.4 Participant Confidentiality
Monitors, auditors, and other authorized agents of the sponsor and/or its designee, the 
IEC(s)/IRB(s) approving this research, as well as that of any other applicable agency(ies), will be 
granted direct access to the study participants’ original medical records for verification of 
clinical study procedures and/or data, without violating the confidentiality of the participants to 
the extent permitted by the law and regulations. In any presentations of the results of this study 
or in publications, the participant’s identity will remain confidential.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 49 of 70
CONFIDENTIAL
13 REPORTING AND PUBLICATION, INCLUDING ARCHIVING
Essential documents are those documents that individually and collectively permit evaluation of 
the study and quality of the data produced. After completion of the study (end of study defined as 
the date of the last visit of the last participant), all documents and data relating to the study will 
be kept in an orderly manner by the investigator in a secure study file. This file will be available 
for inspection by the sponsor or its representatives. Essential documents should be retained for 2 
years after the final marketing approval or for at least 2 years since the discontinuation of clinical 
development of the investigational product. It is the responsibility of the sponsor to inform the 
study center when these documents no longer need to be retained. The investigator must contact 
the sponsor before destroying any study-related documentation. In addition, all participant
medical records and other source documentation will be kept for the maximum time permitted by 
the hospital, institution, or medical practice.
The sponsor must review and approve any results of the study or abstracts for professional 
meetings prepared by the investigator(s). Published data must not compromise the objectives of 
the study. Data from individual study centers in multi-center studies must not be published 
separately.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 50 of 70
CONFIDENTIAL
14 REFERENCES
Beacham BE, Cooper PH, Buchanan CS, Weary PE. Equestrian cold panniculitis in women. 
Arch Dermatol. 1980;116(9):1025–1027.
Bernstein EF, Bloom JD, Basilavecchio LD, Plugis JM. Non-invasive fat reduction of the flanks 
using a new cryolipolysis applicator and overlapping, two-cycle treatments. Lasers Surg Med. 
2014;46(10):731-735.
Boey GE, Wasilenchuk JL. Fat reduction in the inner thigh using a prototype cryolipolysis 
applicator. Dermatol Surg. 2014;40(9):1004-1009.
Carruthers JD, Humphrey S, Rivers JK. Cryolipolysis for reduction of arm fat: safety and 
efficacy of a prototype CoolCup applicator with flat contour. Dermatol Surg. 
2017;43(7):940-949.
Epstein EH Jr, Oren ME. Popsicle panniculitis. N Engl J Med. 1970;282(17):966–967.
Lee KR. Clinical efficacy of fat reduction on the thigh of Korean women through cryolipolysis. J 
Obes Weight Loss Ther. 2013;3(6):203.
Manstein D, Laubach H, Watanabe K, Farinelli W, Zurakowski D, Anderson RR. Selective 
cryolysis: a novel method of non-invasive fat removal. Lasers Surg Med. 2008;40(9):595-604.
Putra IB, Jasuf NK, Dewi NK. Utilisation of cryolipolysis among Asians: a review on efficacy 
and safety. Open Access Maced J Med Sci. 2019;7(9):1548-1554.
Rivers JK, Ulmer M, Vestvik B, Santos S. A customized approach for arm fat reduction using 
cryolipolysis. Lasers Surg Med. 2018;50(7):732-737.
Shek SY, Chan NP, Chan HH. Non-invasive cryolipolysis for body contouring in Chinese-a first 
commercial experience. Lasers Surg Med. 2012;44(2):125-130.
Suh DH, Park JH, Jung HK, Lee SJ, Kim HJ, Ryu HJ. Cryolipolysis for submental fat reduction 
in Asians. J Cosmet Laser Ther. 2018;20(1):24-27.
Wanitphakdeedecha R, Sathaworawong A, Manuskiatti W. The efficacy of cryolipolysis 
treatment on arms and inner thighs. Lasers Med Sci. 2015;30(8):2165-2169.
Zelickson B, Egbert BM, Preciado J, Allison J, Springer K, Rhoades RW, Manstein D. 
Cryolipolysis for noninvasive fat cell reduction: initial results from a pig model. Dermatol Surg. 
2009;35(10):1462-1470.
Zelickson BD, Burns AJ, Kilmer SL. Cryolipolysis for safe and effective inner thigh fat 
reduction. Lasers Surg Med. 2015;47(2):120-127.

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 51 of 70
CONFIDENTIAL
15 APPENDICES

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 52 of 70
CONFIDENTIAL
15.1 Investigator Signature Page
Protocol Title:
CoolSculpting® the Upper Arms and Inner Thighs in Participants of 
Chinese Descent (XinCOOL)
Protocol Number:
MED-MA-PLS-0633
Confidentiality and Current GCP Compliance Statement
I, the undersigned, have reviewed this protocol (and amendments), including appendices, and I 
will conduct the study as described in compliance with this protocol (and amendments), GCP, 
and relevant regulatory guidelines.
Once the protocol has been approved by the IEC/IRB, I will not modify this protocol without 
obtaining prior approval of Allergan and of the IEC/IRB. I will submit the protocol amendments 
and/or any ICF modifications to Allergan and IEC/IRB, and approval will be obtained before any 
amendments are implemented.
I understand that all information obtained during the conduct of the study with regard to the 
participants’ state of health will be regarded as confidential. No participants’ names will be 
disclosed. All participants will be identified by assigned numbers on all CRFs, laboratory 
samples, or source documents forwarded to the sponsor. Clinical information may be reviewed 
by the sponsor or its agents or regulatory agencies. Agreement must be obtained from the 
participant before disclosure of participant information to a third party.
Information developed in this clinical study may be disclosed by Allergan, to other clinical 
investigators, regulatory agencies, or other health authority or government agencies as required.
Investigator Signature
Date
Printed Name
Institution

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 53 of 70
CONFIDENTIAL
15.2 CoolSculpting Procedure Training Guides

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 54 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 55 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 56 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 57 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 58 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 59 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 60 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 61 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 62 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 63 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 64 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 65 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 66 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 67 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 68 of 70
CONFIDENTIAL

Allergan
02Oct2019
MED-MA-PLS-0633
Version 1.0/Page 69 of 70
CONFIDENTIAL

Aller g a n
0 2 Oct 2 0 1 9
M E D -M A -P L S- 0 6 3 3
Versi o n 1. 0/ P a ge 7 0 of 7 0
C O N FI D E N TI A L